Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E62.91 EPS (ttm)6.41 Insider Own0.50% Shs Outstand104.58M Perf Week-0.33%
Market Cap42.14B Forward P/E27.93 EPS next Y14.43 Insider Trans-2.47% Shs Float77.55M Perf Month-1.96%
Income743.00M PEG3.38 EPS next Q2.73 Inst Own70.80% Short Float4.68% Perf Quarter1.70%
Sales4.65B P/S9.06 EPS this Y85.10% Inst Trans-0.15% Short Ratio4.40 Perf Half Y4.93%
Book/sh38.96 P/B10.34 EPS next Y31.98% ROA15.90% Target Price466.64 Perf Year-25.10%
Cash/sh9.99 P/C40.32 EPS next 5Y18.62% ROE24.60% 52W Range329.09 - 592.59 Perf YTD-25.77%
Dividend- P/FCF40.04 EPS past 5Y44.90% ROI16.00% 52W High-32.00% Beta1.24
Dividend %- Quick Ratio3.10 Sales past 5Y55.00% Gross Margin91.40% 52W Low22.45% ATR11.30
Employees4300 Current Ratio3.40 Sales Q/Q21.40% Oper. Margin33.80% RSI (14)48.38 Volatility3.72% 2.71%
OptionableYes Debt/Eq0.09 EPS Q/Q0.00% Profit Margin19.50% Rel Volume0.80 Prev Close400.25
ShortableYes LT Debt/Eq0.09 EarningsAug 04 BMO Payout0.00% Avg Volume824.31K Price402.97
Recom2.30 SMA20-4.04% SMA503.51% SMA200-5.54% Volume663,472 Change0.68%
Aug-05-16Downgrade Robert W. Baird Outperform → Neutral $505 → $448
Jun-29-16Initiated Bernstein Outperform
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Mar-17-16Reiterated Sun Trust Rbsn Humphrey Neutral $450 → $410
Mar-16-16Downgrade Chardan Capital Markets Neutral → Sell $375 → $325
Mar-15-16Initiated Gabelli & Co Buy $574
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $450
Feb-25-16Initiated Citigroup Buy $480
Feb-16-16Upgrade Chardan Capital Markets Sell → Neutral $400 → $375
Feb-10-16Reiterated RBC Capital Mkts Outperform $676 → $668
Feb-10-16Reiterated Leerink Partners Outperform $534 → $505
Feb-10-16Reiterated Barclays Equal Weight $610 → $425
Feb-09-16Reiterated Piper Jaffray Neutral $607 → $443
Jan-27-16Downgrade Canaccord Genuity Buy → Hold $700 → $525
Jan-25-16Downgrade Chardan Capital Markets Neutral → Sell $525 → $400
Jan-20-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Wells Fargo Outperform
Nov-05-15Reiterated RBC Capital Mkts Outperform $665 → $676
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight $593
Aug-27-16 09:12AM  These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a Year at Motley Fool
Aug-24-16 03:00PM  Regeneron ranks as one of most innovative companies by Forbes at
02:09PM  Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Aug-23-16 09:48AM  Regeneron Stock Up on BARDA Deal for MERS Antibodies
Aug-22-16 11:56AM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : August 22, 2016
08:30AM  Regeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus PR Newswire
Aug-19-16 04:19PM  Hunting For Biotech Stocks? Understand The Earnings Formula First
11:04AM  Horizons Orphan Drug Business Faces These Opportunities
07:00AM  No Pain, Potential for Lots of Gain at Morningstar
Aug-16-16 11:00AM  Amgen, Sanofi Cholesterol Drugs Not Cost-Effective, Study Says at Bloomberg
Aug-14-16 04:49PM  3 of Frank Sands' Top 5 Transactions in 2nd Quarter Were Reductions
Aug-12-16 09:30AM  The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
08:53AM  How to Play a Nasdaq Breakout
Aug-11-16 05:30PM  Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
05:05PM  NFL doing everything it can on concussions, Dan Marino says at CNBC
02:41PM  Hall of Famer Dan Marino on his investments
01:05PM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : August 11, 2016
09:31AM  Adverum (ADVM) Reports Narrower-than-Expected Q2 Loss
Aug-09-16 10:34AM  Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016
09:08AM  What Do Analysts Recommend for Regeneron after 2Q16 Earnings?
Aug-08-16 05:46PM  How Did Regeneron Perform in 2Q16?
01:46PM  How Did Regenerons Revenue and Earnings Look in 2Q16?
Aug-05-16 01:44PM  Regeneron: The Downside of High Expectations at
06:55AM  Regeneron Pharma downgraded by Robert W. Baird
Aug-04-16 04:44PM  Regeneron Stock Dips As Earnings Beat And Revenue Lags
01:44PM  [$$] Regeneron's Revenue Jumps on Sales of Eye Treatment Eylea at The Wall Street Journal
12:59PM  Keep Calm and Spend On, Regeneron at Bloomberg
11:33AM  Regeneron (REGN) Tops Q2 Earnings, Keeps '16 Eylea View
11:14AM  Edited Transcript of REGN earnings conference call or presentation 4-Aug-16 12:30pm GMT
11:03AM  Regeneron: EPS Beat and 21% Revenue Growth Not Enough to Impress; Shares Down 4.4% at
10:48AM  Regeneron sticks by 2016 growth forecast for Eylea, shares fall
10:40AM  Merrill Lynch Says the Time to Put Money Into Biotech Is Now at 24/7 Wall St.
08:59AM  The Market In 5 Minutes: Bank Of England Cut Interest Rates For The First Time In 7 Years
08:22AM  Regeneron (REGN) Beats on Q2 Earnings, Retains Eylea View
07:20AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:07AM  Q2 2016 Regeneron Pharmaceuticals Inc Earnings Release - Before Market Open
06:43AM  Regeneron tops 2Q profit forecasts
06:42AM  Eylea sales lift Regeneron quarterly revenue
06:30AM  Regeneron Reports Second Quarter 2016 Financial and Operating Results PR Newswire
05:35AM  Sizzling S&P sectors for summer
Aug-03-16 09:36AM  5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More
Aug-02-16 10:21AM  Amgen, Regeneron Forge New, Separate Cancer Immunotherapy Pacts
08:30AM  Regeneron and Adicet Bio Announce Strategic Collaboration to Discover and Develop Next-Generation Engineered Immune Cell Therapeutics PR Newswire
Aug-01-16 11:58AM  Regeneron (REGN) Q2 Earnings: Can the Stock Surprise?
09:58AM  Regeneron Is Regenerating Lost Profits
09:09AM  Vertexs Orkambi to Treat Cystic Fibrosis Drives Companys Growth
02:00AM  Sanofi and Regeneron Announce EMA Acceptance for Review of Marketing Authorisation Application for Sarilumab PR Newswire
Jul-31-16 11:14AM  BioMarin: Why So Many Buy Recommendations?
Jul-29-16 09:43AM  Better Buy: Regeneron Pharmaceuticals vs. Pfizer at Motley Fool
Jul-26-16 05:17PM  What Do Analysts Recommend for Shire?
Jul-25-16 11:05AM  Understanding Improvement in Vertex Pharmaceuticalss PE Multiple
Jul-22-16 07:53PM  Whats Been Beating down the Fidelity Growth Company Fund in 2016?
07:00PM  Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week
04:11PM  Eli Lilly, J&J, Novo Battle Diabetes -- And Each Other
01:12PM  What Do Analysts Recommend for United Therapeutics?
Jul-21-16 03:56PM  Analysts Gauge Alexion Pharmaceuticals Return Potential
Jul-20-16 12:03PM  Why I Bought Shares of Regeneron Pharmaceuticals Inc. Last Week at Motley Fool
Jul-19-16 07:21AM  3 Biotech Stocks to Buy and Hold at Motley Fool
Jul-18-16 04:15PM  Regeneron Pharmaceuticals, Inc. Value Analysis (NASDAQ:REGN) : July 18, 2016
09:30AM  Regeneron Announces Upcoming 2016 Investor Conference Presentation PR Newswire
Jul-13-16 04:31PM  Here's Why Regeneron Pharmaceuticals, Inc. Dropped Another 12% in June at Motley Fool
11:39AM  Biotech: 'We Would Not Be Surprised to See Volatility Continue' at
09:05AM  Regenerons Dupilumab: How Much Potential Does It Hold?
08:30AM  Regeneron Announces 2016 Winners of the Regeneron Prize for Creative Innovation PR Newswire
Jul-12-16 09:06PM  Regenerons Robust Pipeline
02:40PM  5 Stocks Set to Soar on Bullish Earnings
10:20AM  Amgen's Repatha Gains FDA Approval for New Dosing Option
09:27AM  Instant Analysis: Amgen's Latest Approval Raises the Bar Yet Again on Regeneron Pharmaceuticals Inc and Sanofi SA (ADR) at Motley Fool
09:08AM  Whats Driving Regenerons Premium Valuation?
07:00AM  Award-Winning Chef Elizabeth Falkner Reveals Her Struggle with Atopic Dermatitis to Highlight the Physical and Psychological Impact of the Disease PR Newswire
Jul-11-16 12:06PM  Whats behind Regenerons Operating Efficiency?
09:07AM  Is It Slower Growth for Regenerons Eylea in 2016 and 2017?
08:03AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : July 11, 2016
Jul-08-16 09:25PM  Inside Alnylam Pharmaceuticalss Analyst Recommendations in 2016
03:03PM  Regeneron in 2Q16: How Much Revenue Growth Could It Have?
03:03PM  Regeneron: How Much Upward Potential Does It Have?
09:30AM  Regeneron to Report Second Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on August 4, 2016 PR Newswire
Jul-07-16 04:40PM  Surprise: JNJ Just Did Celgene a Huge Favor
Jul-06-16 04:18PM  Strong Q2 For Biotech Forecast As Drug Prices Keep Going Up
Jul-05-16 01:00AM  Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan PR Newswire
Jul-04-16 09:21AM  3 Top Healthcare Stocks to Buy Now at Motley Fool
Jul-01-16 05:18PM  3 Potential Stock-Moving Drug Events In The Second Half Of 2016
10:02AM  Here's Why Regeneron Pharmaceuticals Inc Is Down 35% This Year at Motley Fool
Jun-29-16 03:24PM  Three Biotech GiantsBut Only Two are Worth Buying at
01:15PM  Esperion Therapeutics Inc Sinks After FDA Says, "Ask Us in 2019" at Motley Fool
12:03PM  Regeneron CEO Schleifer: Drug Pricing Conundrum
10:24AM  Drug Companies Need to Tell a Better Story, Regeneron Says at Bloomberg
10:24AM  Drug Companies Need to Tell a Better Story, Regeneron CEO Says
Jun-28-16 04:31PM  Novartis, Xencor Ink $2.4 Billion Licensing Deal In Blood Cancer
Jun-27-16 09:42PM  The Largest Drug Pipelines Will Surprise You
12:55PM  Regeneron acquires Pitney Bowes building in Rensselaer Tech Park at
Jun-25-16 02:01PM  3 Biotech Stocks to Buy Now for the Long Haul at Motley Fool
12:20AM  [$$] Biotech Labs Birth New Drugsand New Fortunes at The Wall Street Journal
Jun-24-16 04:34PM  How Does Brexit Affect Biotech Stocks? Wall Street Weighs In
Jun-23-16 10:10AM  Company News for June 23, 2016
Jun-22-16 04:57PM  Medicare 'Death Panel' Is On Ice; Biotechs Rally
04:04PM  Verifone, Biogen Crash Wednesdays 52-Week Low Club at 24/7 Wall St.
03:56PM  Regeneron Tries to Recover From Lows
12:51PM  Stocks Erased Gains; Biotechs, KB Home Jump As Tesla Dives
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration and diabetic macular edema, as well as macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of low-density lipoprotein cholesterol; and ARCALYST for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrens. The company is also developing trap-based clinical product EYLEA for the treatment of Neovascular Glaucoma; antibody-based clinical products comprising Praluent, Sarilumab, Dupilumab, REGN2810, REGN2176-3, Fasinumab, REGN2222, Evinacumab, REGN1033, REGN1908-1909, REGN1979, and Nesvacumab/aflibercept; and ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer. It has collaborations with Sanofi, Bayer HealthCare, and Mitsubishi Tanabe Pharma Corporation for the development of antibody-based clinical based products. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDSTEIN JOSEPH LDirectorJul 29Option Exercise273.672,125581,54915,125Aug 01 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 29Sale425.002,125903,12513,000Aug 01 04:04 PM
RYAN ARTHUR FDirectorMay 24Sale396.641,000396,64039,500May 25 04:02 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 18Sale385.774,4131,702,4031,921May 19 04:26 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 17Option Exercise30.639,460289,76011,381May 19 04:26 PM
VAGELOS P ROYChairman of the BoardMay 12Option Exercise20.32230,6844,687,499563,564May 13 04:40 PM
GOLDSTEIN JOSEPH LDirectorApr 06Option Exercise177.821,000177,82014,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 06Sale425.002,000850,00013,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 01Option Exercise177.822,000355,64016,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorApr 01Sale400.002,000800,00014,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorMar 21Option Exercise177.822,000355,64016,000Mar 21 04:27 PM
GOLDSTEIN JOSEPH LDirectorMar 21Sale375.002,000750,00014,000Mar 21 04:27 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 29Option Exercise52.033,954205,72710,820Dec 29 07:44 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 29Sale552.083,9542,182,9246,866Dec 29 07:44 PM
Aberman Michael SSVP Strategy Investor RelationDec 17Option Exercise24.004,00096,00016,498Dec 18 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 16Option Exercise52.031,92199,95017,742Dec 18 04:27 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise52.031,92199,9506,866Dec 18 04:28 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise52.031,92199,950501,921Dec 18 04:26 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 16Option Exercise52.031,92199,9501,921Dec 18 04:27 PM
STAHL NEILEVP Research and DevelopmentDec 16Option Exercise52.031,92199,95027,594Dec 18 04:27 PM
BROWN MICHAEL SDirectorDec 10Option Exercise177.823,000533,4603,000Dec 11 04:14 PM
BROWN MICHAEL SDirectorDec 10Sale546.453,0001,639,3650Dec 11 04:14 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 02Sale549.0343,34823,799,539500,000Dec 04 04:13 PM
SING GEORGE LDirectorNov 18Option Exercise19.693,00059,070115,772Nov 20 04:04 PM
VAGELOS P ROYChairman of the BoardNov 18Sale587.9017,24010,135,312334,611Nov 19 04:20 PM
SING GEORGE LDirectorNov 18Sale580.00500290,0004,500Nov 20 04:04 PM
SING GEORGE LDirectorNov 18Sale580.003,0001,740,000112,772Nov 20 04:04 PM
STAHL NEILEVP Research and DevelopmentNov 09Sale560.0522,10112,377,55922,029Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 06Sale563.0020,00011,260,06844,130Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 05Option Exercise28.29100,0002,828,50097,029Nov 09 05:10 PM
VAGELOS P ROYChairman of the BoardNov 03Sale580.233,9852,312,217351,851Nov 04 04:05 PM
VAGELOS P ROYChairman of the BoardNov 02Sale580.1813,2577,691,446355,836Nov 04 04:05 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriNov 02Sale571.6143,34824,778,125543,348Nov 03 04:20 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriOct 30Option Exercise11.64182,8182,128,002682,818Nov 03 04:20 PM
BROWN MICHAEL SDirectorSep 21Option Exercise57.113,000171,3303,000Sep 22 02:39 PM
BROWN MICHAEL SDirectorSep 21Sale551.553,0001,654,6500Sep 22 02:39 PM
BAKER CHARLES ADirectorSep 17Option Exercise18.615,00093,05014,000Sep 18 04:06 PM
BAKER CHARLES ADirectorSep 17Sale550.005,0002,750,0009,000Sep 18 04:06 PM
SCHLEIFER LEONARD SPresident & CEOSep 02Option Exercise402.697,2262,909,83849,313Sep 03 04:59 PM
LAROSA JOSEPH JSVP General Counsel and SecretSep 01Option Exercise59.201,68999,98916,756Sep 02 04:04 PM